Codexis Revenue and Competitors
Estimated Revenue & Valuation
- Codexis's estimated annual revenue is currently $101.3M per year.
- Codexis received $25.3M in venture funding in April 2017.
- Codexis's estimated revenue per employee is $379,363
- Codexis's total funding is $162M.
- Codexis's current valuation is $1.7B. (January 2022)
Employee Data
- Codexis has 267 Employees.
- Codexis grew their employee count by -21% last year.
Codexis's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO and President | Reveal Email/Phone |
2 | Chief Legal and Compliance Officer, General Counsel | Reveal Email/Phone |
3 | Chief Legal and Compliance Officer, General Counsel and Secretary | Reveal Email/Phone |
4 | Sr. VP, Strategic Development | Reveal Email/Phone |
5 | VP, Corporate Law | Reveal Email/Phone |
6 | VP Finance | Reveal Email/Phone |
7 | SVP & General Manager, Performance Enzymes | Reveal Email/Phone |
8 | SVP, Research | Reveal Email/Phone |
9 | SVP, Product Operations | Reveal Email/Phone |
10 | VP Information Technology | Reveal Email/Phone |
Codexis Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.2M | 22 | 5% | N/A | N/A |
What Is Codexis?
Codexis, Inc. is a leading protein engineering company applying innovative technologies to Unlock the Power of Proteins. Our proprietary CodeEvolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. Codexis revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. You get precisely the protein you need for the job you want it to do. Guided by proprietary artificial intelligence software and advanced high-throughput screening systems, Codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. Since 2002, Codexis in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough developments in pharmaceuticals, biotherapeutics, food & beverage, and a wide range of other industries.
keywords:Biotechnology,E-Commerce,Food & Beverages,Healthcare,Pharmaceuticals$162M
Total Funding
267
Number of Employees
$101.3M
Revenue (est)
-21%
Employee Growth %
$1.7B
Valuation
N/A
Accelerator
Codexis News
Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Codexis has set its FY 2022 guidance at EPS.Parties that...
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance...
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance...
Codexis, Inc. (Nasdaq: CDXS), a Redwood City, Calif.-based synthetic biology company, received a $50 million investment from Casdin Capital, LLC. Casdin, a New York City-based life science-focused investment firm, has invested through the purchase of shares of Codexis’ common stock in a private ...
Less than six months after filing to go public, Codexis, one of several makers of microbes and catalysts used to generate green fuels and chemicals, debuted on the Nasdaq this morning under the symbol CDXS. But the news is bittersweet for the cleantech sector. Yes, the company made it to market ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $43M | 276 | 47% | $350M |
#2 | $61.2M | 279 | -3% | $96.3M |
#3 | $7.5M | 280 | 51% | N/A |
#4 | $42.9M | 285 | 18% | $45M |
#5 | $93.2M | 289 | 25% | $135.1M |
Codexis Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2002-10-07 | $25.0M | Private Placement | CMEA Ventures, Pequot Ventures | Article |
2004-07-28 | $10.0M | Undisclosed | Pfizer | Article |
2006-08-25 | $37.0M | D | Bio*One Capital Pte Ltd | Article |
2017-04-10 | $25.3M | Undisclosed | Jefferies LLC | Article |